BACKGROUND AIMS: Bone marrow stromal cells (BMSC) are being used for immune modulatory, anti-inflammatory and tissue engineering applications, but the properties responsible for these effects are not completely understood. Human BMSC were characterized to identify factors that might be responsible for their clinical effects and biomarkers for assessing their quality. METHODS: Early passage BMSC prepared from marrow aspirates of seven healthy subjects were compared with three human embryonic stem cell (hESC) samples, CD34(+) cells from three healthy subjects and three fibroblast cell lines. The cells were analyzed with oligonucleotide expression microarrays with more than 35 000 probes. RESULTS: BMSC gene expression signatures of BMSC differed from those of hematopoietic stem cells (HSC), hESC and fibroblasts. Genes upregulated in BMSC were involved with cell movement, cell-to-cell signaling and interaction and proliferation. The upregulated genes most probably belonged to pathways for integrin signaling, integrin-linked kinase (ILK) signaling, NF-E2-related factor-2 (NFR2)-mediated oxidative stress response, regulation of actin-based motility by Rho, actin cytoskeletal signaling, caveolar-mediated endocytosis, clathrin-mediated endocytosis and Wingless-type MMTV integration site (Wnt/β catenin signaling. Among the most highly upregulated genes were structural extracellular matrix (ECM) proteins (α5 and β5 integrin chains, fibronectin and collagen type IIIα1 and Vα1) and functional EMC proteins [connective tissue growth factor (CTGF), transforming growth factor beta-induced protein (TGFBI) and A disintegrin and metalloproteinase (ADAM12)]. CONCLUSIONS: Global analysis of human BMSC suggests that they are mobile, metabolically active, proliferative and interactive cells that make use of integrins and integrin signaling. They produce abundant ECM proteins that may contribute to their clinical immune modulatory and anti-inflammatory effects.
BACKGROUND AIMS: Bone marrow stromal cells (BMSC) are being used for immune modulatory, anti-inflammatory and tissue engineering applications, but the properties responsible for these effects are not completely understood. Human BMSC were characterized to identify factors that might be responsible for their clinical effects and biomarkers for assessing their quality. METHODS: Early passage BMSC prepared from marrow aspirates of seven healthy subjects were compared with three human embryonic stem cell (hESC) samples, CD34(+) cells from three healthy subjects and three fibroblast cell lines. The cells were analyzed with oligonucleotide expression microarrays with more than 35 000 probes. RESULTS: BMSC gene expression signatures of BMSC differed from those of hematopoietic stem cells (HSC), hESC and fibroblasts. Genes upregulated in BMSC were involved with cell movement, cell-to-cell signaling and interaction and proliferation. The upregulated genes most probably belonged to pathways for integrin signaling, integrin-linked kinase (ILK) signaling, NF-E2-related factor-2 (NFR2)-mediated oxidative stress response, regulation of actin-based motility by Rho, actin cytoskeletal signaling, caveolar-mediated endocytosis, clathrin-mediated endocytosis and Wingless-type MMTV integration site (Wnt/β catenin signaling. Among the most highly upregulated genes were structural extracellular matrix (ECM) proteins (α5 and β5 integrin chains, fibronectin and collagen type IIIα1 and Vα1) and functional EMC proteins [connective tissue growth factor (CTGF), transforming growth factor beta-induced protein (TGFBI) and A disintegrin and metalloproteinase (ADAM12)]. CONCLUSIONS: Global analysis of human BMSC suggests that they are mobile, metabolically active, proliferative and interactive cells that make use of integrins and integrin signaling. They produce abundant ECM proteins that may contribute to their clinical immune modulatory and anti-inflammatory effects.
Authors: N Meuleman; G Vanhaelen; T Tondreau; P Lewalle; J Kwan; J Bennani; P Martiat; L Lagneaux; D Bron Journal: Haematologica Date: 2008-01 Impact factor: 9.941
Authors: Yifu Zhou; Suna Wang; Zuxi Yu; Robert F Hoyt; Vandana Sachdev; Pamela Vincent; Andrew E Arai; Minjung Kwak; Sandra Sczerba Burkett; Keith A Horvath Journal: Biochem Biophys Res Commun Date: 2009-10-21 Impact factor: 3.575
Authors: Hind Lal; Suresh K Verma; Donald M Foster; Honey B Golden; John C Reneau; Linley E Watson; Hitesh Singh; David E Dostal Journal: Front Biosci (Landmark Ed) Date: 2009-01-01
Authors: Marina C Prewitz; F Philipp Seib; Malte von Bonin; Jens Friedrichs; Aline Stißel; Christian Niehage; Katrin Müller; Konstantinos Anastassiadis; Claudia Waskow; Bernard Hoflack; Martin Bornhäuser; Carsten Werner Journal: Nat Methods Date: 2013-06-23 Impact factor: 28.547
Authors: Pamela G Robey; Sergei A Kuznetsov; Jiaqiang Ren; Harvey G Klein; Marianna Sabatino; David F Stroncek Journal: Bone Date: 2014-07-24 Impact factor: 4.398
Authors: Hisashi Koide; Kenn Holmbeck; Julian C Lui; Xiaoxiao C Guo; Paul Driggers; Tiffany Chu; Ichiro Tatsuno; Caroline Quaglieri; Tomoshige Kino; Jeffrey Baron; Marian F Young; Pamela G Robey; James H Segars Journal: J Bone Miner Res Date: 2015-05-10 Impact factor: 6.741
Authors: Sofieke E Klamer; Carlijn G M Kuijk; Peter L Hordijk; C Ellen van der Schoot; Marieke von Lindern; Paula B van Hennik; Carlijn Voermans Journal: Cell Adh Migr Date: 2013-10-08 Impact factor: 3.405
Authors: Shoba Amarnath; Jason E Foley; Don E Farthing; Ronald E Gress; Arian Laurence; Michael A Eckhaus; Jean-Yves Métais; Jeremy J Rose; Frances T Hakim; Tania C Felizardo; Austin V Cheng; Pamela G Robey; David E Stroncek; Marianna Sabatino; Minoo Battiwalla; Sawa Ito; Daniel H Fowler; Austin J Barrett Journal: Stem Cells Date: 2015-04 Impact factor: 6.277
Authors: Laurence C Cheung; Deborah H Strickland; Meegan Howlett; Jette Ford; Adrian K Charles; Karen M Lyons; David R Brigstock; Roel Goldschmeding; Catherine H Cole; Warren S Alexander; Ursula R Kees Journal: Haematologica Date: 2014-04-11 Impact factor: 9.941